---
document_datetime: 2024-10-18 09:33:57
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/herzuma-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: herzuma-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 10.3857247
conversion_datetime: 2025-12-26 09:12:39.120476
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Herzuma

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0066               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 17/10/2024                          |                                             | PL                               |           |
| II/0061/G            | This was an application for a group of variations.                                               | 05/09/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| product - Other variation B.II.c.3.a.2 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                      |            |     |    | B.I.b.1.z - Change in   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|-------------------------|
| IB/0065 | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                       | 09/08/2024 | n/a |    |                         |
| N/0064  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                          | 30/07/2024 |     | PL |                         |
|         | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation A.7 - Administrative change - Deletion of manufacturing sites | 20/06/2024 | n/a |    | IA/0063/G               |
| IB/0062 | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                       | 17/04/2024 | n/a |    |                         |

<div style=\"page-break-after: always\"></div>

| IAIN/0060/G   | This was an application for a group of variations.                                                               | 14/12/2023   | 16/02/2024   | Annex II and PL   |
|---------------|------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|
| IA/0059       | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation       | 20/09/2023   | n/a          |                   |
| N/0058        | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                 | 19/09/2023   | 16/02/2024   | PL                |
| IB/0057       | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 26/06/2023   | n/a          |                   |
| IAIN/0056     | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site               | 13/03/2023   | n/a          |                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0055   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                     | 24/01/2023   | 16/02/2024   | Annex II and PL        |                                                                                                                                                                                                                                                                       |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0054   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                     | 24/01/2023   | 16/02/2024   | Annex II and PL        |                                                                                                                                                                                                                                                                       |
| R/0050      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                    | 15/09/2022   | 09/12/2022   | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Herzuma in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| N/0053      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                           | 30/09/2022   | 16/02/2024   | PL                     |                                                                                                                                                                                                                                                                       |
| IA/0052/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.e.1.b.3 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Deletion of an immediate packaging | 15/07/2022   | n/a          |                        |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                    | container without a complete deletion of a strength or pharmaceutical form B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State   |            |            |      |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| PSUSA/3010/ 202109 | Periodic Safety Update EU Single assessment - trastuzumab                                                                                                                                                                                                                                          | 10/06/2022 | n/a        |      | PRAC Recommendation - maintenance |
| IA/0051            | B.I.c.z - Container closure system of the AS - Other variation                                                                                                                                                                                                                                     | 24/05/2022 | n/a        |      |                                   |
| N/0049             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                   | 06/04/2022 | 09/12/2022 | PL   |                                   |
| II/0038            | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                     | 03/02/2022 | n/a        |      |                                   |
| IA/0048            | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                      | 31/01/2022 | 09/12/2022 | SmPC |                                   |
| IB/0046/G          | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                       | 25/01/2022 | n/a        |      |                                   |

<div style=\"page-break-after: always\"></div>

| II/0041/G   | This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP   | 09/12/2021   | n/a        |                       |                    |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------|
| IA/0045     | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                | 06/12/2021   | n/a        |                       |                    |
| IB/0044     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                         | 16/11/2021   | 16/12/2021 | SmPC, Annex II and PL |                    |
| N/0043      | Minor change in labelling or package leaflet not SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/09/2021   | 16/12/2021 | PL                    | connected with the |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/09/2021   | n/a        |             | IB/0042       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------|
| IB/0040   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 26/07/2021   | 16/12/2021 | SmPC and PL |               |
| IA/0039/G | This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its test method | 26/04/2021   | n/a        |             | corresponding |
| II/0035/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/03/2021   | n/a        |             |               |

<div style=\"page-break-after: always\"></div>

|         | - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.e.1.b.2 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Sterile medicinal products and   |            |            |                 | A.4 biological/immunological   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------|
| IA/0037 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/02/2021 | 16/12/2021 | Annex II and PL |                                |
| IB/0036 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 15/01/2021 | 16/12/2021 | SmPC and PL     |                                |

<div style=\"page-break-after: always\"></div>

| II/0032/G   | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation   | 10/12/2020   | n/a        |    |              |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|--------------|
| II/0031     | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a method                                                                                                                                                                                                                                                                                                                | 22/10/2020   | n/a        |    | biol/immunol |
| N/0033      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/09/2020   | 16/12/2021 | PL |              |
| IB/0034     | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/09/2020   | n/a        |    |              |
| IB/0030     | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time                                                                                                                                                                                                                                                                                                                                                                                                        | 26/06/2020   | n/a        |    |              |

<div style=\"page-break-after: always\"></div>

|           | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |      |                        |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------|
| N/0029    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20/05/2020 | 15/09/2020 | PL   |                        |
| IB/0028   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                               | 03/04/2020 | 15/09/2020 | SmPC |                        |
| IB/0027/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of | 27/03/2020 | n/a        |      | an obsolete parameter) |
| IB/0026/G | This was an application for a group of variations. B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                                                                                                                              | 19/03/2020 | n/a        |      |                        |

<div style=\"page-break-after: always\"></div>

|           | - Change to in-process tests or limits during the manufacture of the finished - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |             | B.II.b.5.z applied product   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------|
| IB/0025/G | This was an application for a group of variations. B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data) B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved                                                                                                                                                                                                                                     | 21/01/2020 | 15/09/2020 | SmPC and PL | stability protocol           |
| IA/0024/G | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - Tightening of specification limits B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.b - Change to in-process tests or limits the manufacture of the finished | 15/11/2019 | n/a        |             | applied during               |

<div style=\"page-break-after: always\"></div>

|                    | product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                                                                                                                                                                                                    |            |            |             |                                                                                                                                           |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023            | C.I.13: Submission of the final report of study CT-P6 3.2; this is a phase 3, double blind, randomized, parallel-group, active-controlled study to compare the efficacy and safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant treatment in patients with HER2 positive early breast cancer. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 10/10/2019 | n/a        |             |                                                                                                                                           |
| PSUSA/3010/ 201809 | Periodic Safety Update EU Single assessment - trastuzumab                                                                                                                                                                                                                                                                                                                                                                                         | 29/05/2019 | 01/08/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3010/201809. |
| IB/0021            | C.I.2.z - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Other variation                                                                                                                                                                                                                                                                          | 10/07/2019 | 15/09/2020 | SmPC and PL |                                                                                                                                           |
| IB/0022/G          | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                | 03/07/2019 | n/a        |             |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |     | variation             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|
| IAIN/0020 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                      | 12/04/2019 | n/a |                       |
| II/0012   | B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection                                                                                                                                                                                                                                                                                     | 28/03/2019 | n/a |                       |
|           | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits Change in the specification parameters                                                | 21/03/2019 | n/a | IA/0019/G B.I.b.1.c - |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.II.b.5.a - Change to applied during the manufacture product - Tightening of B.II.c.1.a - Change in and/or limits of an excipient specification limits B.II.e.3.a - Change in immediate packaging changes to an approved B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply national pharmacopoeia to comply with an update of the Ph. Eur. or national Member State B.III.2.b - Change to comply national pharmacopoeia to comply with an update   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                 | Member State                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------|
| IB/0018   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                          | 07/03/2019 | 01/08/2019 | SmPC and PL     |                                     |
| IG/1053/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 28/01/2019 | 01/03/2019 | Annex II and PL | Not including batch control/testing |
| IB/0015/G | This was an application for a group of variations. B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved                                                                                                                                                                                                                                | 14/01/2019 | 01/03/2019 | SmPC and PL     | stability protocol                  |
| IB/0014   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                          | 12/11/2018 | 01/03/2019 | SmPC and PL     |                                     |

<div style=\"page-break-after: always\"></div>

| IAIN/0013   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                | 26/10/2018   | n/a        |                                  |                |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------|
| II/0006     | B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products                                                                                                                                                                                                                                                                          | 20/09/2018   | 01/03/2019 | SmPC, Annex II, Labelling and PL |                |
| II/0005     | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                | 13/09/2018   | n/a        |                                  |                |
| IB/0011/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 23/08/2018   | 01/03/2019 | SmPC and PL                      | new additional |

<div style=\"page-break-after: always\"></div>

|           | the MAH                                                                                                                                                                                                                                                                                                                                                       |            |     |                                                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------|
| IB/0009/G | for a group of variations. B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished | 17/08/2018 | n/a | This was an application product - Other variation |
| IB/0008   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                        | 19/07/2018 | n/a |                                                   |
| IAIN/0007 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                            | 11/06/2018 | n/a |                                                   |
| IAIN/0004 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                            | 30/04/2018 | n/a |                                                   |
| IB/0003/G | This was an application for a group of variations. B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g.                                                                                               | 27/03/2018 | n/a |                                                   |

<div style=\"page-break-after: always\"></div>

|           | duplication of line) B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect information   |            |            |                        | the product   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------|
| IB/0002   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 15/03/2018 | 01/03/2019 | SmPC                   |               |
| IAIN/0001 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 12/03/2018 | 01/03/2019 | SmPC, Labelling and PL |               |